Monte Rosa Therapeutics GLUE
NASDAQ GLUE
$11.22 -0.14 (-1.23%)
At close: Oct 21, 2026 · 4:00 PM EDT

Monte Rosa Therapeutics (GLUE) EV to EBIT (2025)

Updated

Monte Rosa Therapeutics' EV to EBIT was 47.26 in Q3 2025, up 134.7% from the prior quarter.

Analysis

Monte Rosa Therapeutics (GLUE) EV to EBIT (2025) Analysis & Trends

On a trailing twelve-month basis, Monte Rosa Therapeutics' EV to EBIT was 3.53 through Sep 30, 2025.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Monte Rosa Therapeutics 1.14 Bn 550.40 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 47.26
Jun 30, 2025 20.14
API Access

Monte Rosa Therapeutics EV to EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=GLUE&period=max&api_key=YOUR_API_KEY